Krystal Biotech’s Promising Aesthetic Developments and Positive Phase I Results Justify Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating on July 22.

Sami Corwin has given his Buy rating due to a combination of factors that highlight Krystal Biotech’s promising developments in their aesthetic product line. The recent positive results from the Phase I PEARL-2 study of Jeune Aesthetics’ KB304, aimed at treating wrinkles of the décolleté, demonstrated significant improvements in patient and investigator assessments compared to placebo. This is a notable achievement as the product utilizes a non-integrating HSV-1-based vector to deliver transgenes encoding collagen III and elastin, leading to meaningful aesthetic enhancements.
Additionally, the safety profile of KB304 aligns with previous clinical experiences, showing only mild to moderate adverse events that decreased with subsequent doses. The company’s plan to advance KB304 into Phase II studies by the first half of 2026 further supports the potential for future success. These factors collectively contribute to the positive outlook and justify the Buy rating for Krystal Biotech’s stock.

In another report released on July 22, TD Cowen also maintained a Buy rating on the stock with a $202.00 price target.